Cancer Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Astrocytoma
Study findings from Royal North Shore Hospital provide new insights into astrocytoma
December 23rd, 2008
According to recent research from Australia, "Reduction in the mRNA and protein expression of lipocalin-like prostaglandin D-2 (PGD(2)) synthase (PGDS), the main arachiclonic acid metabolite produced in neurons and glial cells of the central nervous system, is a significant biological event involved in the malignant progression of astrocytomas and is predictive of poor survival." "In vitro, the addition of the main PGDS metabolite, PGD(2), to A172 glioblastoma cells devoid of PGDS resulted in antiproliferative activity and cell death. In vitro PGD(2) substitution also enhanced the efficacy of cyclo-oxygenase-2 inhibitors," wrote C.A. Payne and colleagues, Royal North...
Source: Cancer Weekly (2008-12-23)
|
